ICU Medical (NASDAQ:ICUI) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of ICU Medical (NASDAQ:ICUI) in a report released on Thursday, Benzinga reports.

Separately, Raymond James raised shares of ICU Medical from a market perform rating to an outperform rating and set a $135.00 target price on the stock in a report on Monday, June 17th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, ICU Medical presently has an average rating of Moderate Buy and a consensus target price of $138.33.

ICU Medical Stock Performance

NASDAQ:ICUI traded up $1.36 during mid-day trading on Thursday, hitting $152.71. 567,547 shares of the company traded hands, compared to its average volume of 281,822. The stock’s fifty day moving average price is $121.24 and its 200-day moving average price is $108.10. The company has a quick ratio of 1.09, a current ratio of 2.61 and a debt-to-equity ratio of 0.76. ICU Medical has a one year low of $78.28 and a one year high of $153.55. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of -62.33 and a beta of 0.69.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 2.63% and a positive return on equity of 5.38%. The company had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. During the same period in the prior year, the firm posted $1.58 EPS. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. Research analysts anticipate that ICU Medical will post 3.5 earnings per share for the current fiscal year.

Insider Transactions at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 300 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $104.95, for a total transaction of $31,485.00. Following the completion of the transaction, the director now owns 2,129 shares in the company, valued at $223,438.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Elisha W. Finney sold 300 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the sale, the director now directly owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christian B. Voigtlander sold 12,539 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $103.95, for a total value of $1,303,429.05. The disclosure for this sale can be found here. Insiders have sold 14,889 shares of company stock valued at $1,630,340 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently made changes to their positions in ICUI. Innealta Capital LLC purchased a new stake in ICU Medical in the 2nd quarter worth about $32,000. Motco purchased a new stake in shares of ICU Medical in the first quarter worth approximately $29,000. GAMMA Investing LLC lifted its stake in shares of ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares during the last quarter. EntryPoint Capital LLC boosted its holdings in ICU Medical by 731.5% during the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 395 shares during the period. Finally, Russell Investments Group Ltd. grew its position in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.